View benefits and risks of Avastin® (bevacizumab) treatment for 1L metastatic non-squamous non-small cell lungcancer (NSCLC). See full safety for more information. Bevacizumab combined with platinum‐based double agent chemotherapy has been reported to improve the objective response rate (ORR) and progression‐free survival (PFS) in patients with advanced nonsquamous non‐small cell lungcancer (NSCLC), but also cause more adverse effects. Oct 15, 2024 · Abstract Introduction: The advent of bevacizumab has considerably transformed the therapeutic landscape for non-small cell lungcancer (NSCLC) patients devoid of specific genetic mutations. Oct 5, 2006 · Bevacizumab works by blocking a protein called VEGF, which some cancer cells produce in large amounts. Blocking VEGF may prevent the growth of new blood vessels that tumors need to grow. Jan 23, 2026 · Bevacizumab (Avastin) is a targeted cancer drug. It is a treatment for a number of different cancer types. Find out how you have it, possible side effects and other important information. The open-label, randomized phase 3b Avastin in All Lines Lung (AvaALL) study assessed the efficacy and safety of bevacizumab beyond first progression in advanced NSCLC following bevacizumab maintenance therapy. ARIES (Avastin Regimens: Investigation of Effectiveness and Safety), a prospective observational cohort study, evaluated outcomes in a large, community-based population of patients with first-line NSCLC.